Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot phase III trial of electrocoagulation versus topical sinecatechins versus topical cidofovir for high-grade anal intraepithelial neoplasia in HIV-positive men who have sex with men
2018-001730-18Phase 3Active
- Sponsor
- Vall d'Hebron Research Institute
- Start
- Apr 2019
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Theaphenon E and cidofovir in anal intraepithelial neoplasia (AIN) (3 arms), sponsored by Vall d'Hebron Research Institute. Primary endpoint: Proportion of patients with complete or partial regression of HGAIN. Started Apr 2019; status: active.
02
Drugs
Theaphenon Ecidofovir
03
Conditions
anal intraepithelial neoplasia (AIN)
Beyond the preview
Go deeper on 2018-001730-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001730-18.